Added to YB: 2026-02-06
Pitch date: 2026-02-04
IKT [bullish]
Inhibikase Therapeutics, Inc.
+49.35%
current return
Author Info
Vulpes’s Substack - B.S/PhD in Biology. Former analyst at biotech-specialist hedge fund. Citizen of Graham and Doddsville. Boston, MA. Sign up for the newsletter.
Company Info
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Market Cap
$438.8M
Pitch Price
$1.54
Price Target
7.30 (+217%)
Dividend
N/A
EV/EBITDA
-4.23
P/E
-5.57
EV/Sales
N/A
Sector
Biotechnology
Category
growth
The One PAH Drug That Already Worked — And Why Inhibikase Owns the Comeback
IKT: Developing gut-masked imatinib prodrug for PAH. Imatinib proven effective in Ph3 but discontinued due to brain bleeds (only w/ anticoagulants, no longer used) & limited IP. AVTE's inhaled version failed, suggesting systemic dosing needed. GOSS readout Feb w/ inhaled seralutinib. IKT trades $550M FD vs comparable $INSM +$5.7B on PAH data, $GOSS $1B pre-Ph3. Blockbuster potential $2.5-5B peak sales. Ph3 readout ~3.5yrs, interim safety 1-1.5yrs. High PoS, catalyst desert creates opportunity.
Read full article (9 min)